Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)

PHASE3CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Erythropoietic Protoporphyria
Interventions
DRUG

Afamelanotide

One 16mg subcutaneous implant every 2 months for 9 months.

DRUG

Placebo

One 16mg subcutaneous implant every 2 months for 9 months.

Trial Locations (8)

9

Beaumont Hospital, Department of Dermatology, Dublin

40225

Department of Dermatology , Heinrich-Heine-University Duesseldorf, Düsseldorf

92701

Centre Français des Porphyries, Hôpital Louis Mourier, Colombes

Unknown

HUS:n Iho-ja allergiasairaala (Skin and Allergy Hospital), Helsinki

Academisch Ziekenhuis Maastricht, Maastricht

Erasmus Medical Center, Rotterdam

St Woolos Hospital, Newport

M6 8HD

Photobiology Unit - Hope Hospital, University of Manchester, Manchester

All Listed Sponsors
lead

Clinuvel Pharmaceuticals Limited

INDUSTRY